LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro by Huang, Tien-sheng et al.
BioMed  Central
Page 1 of 13
(page number not for citation purposes)
Molecular Cancer
Open Access Research
LEDGF/p75 has increased expression in blasts from 
chemotherapy-resistant human acute myelogenic leukemia 
patients and protects leukemia cells from apoptosis in vitro
Tien-sheng Huang1,3,4, Line M Myklebust1, Endre Kjarland3, 
Bjørn Tore Gjertsen2, Frederic Pendino1, Øystein Bruserud2, 
Stein Ove Døskeland3 and Johan R Lillehaug*1
Address: 1Department of Molecular Biology, University of Bergen, Bergen, Norway, 2Institute of Medicine, Hematology Section, Haukeland 
University Hospital, Bergen, Norway, 3Department of Biomedicine, University of Bergen, Bergen, Norway and 4Gades Institute and Department 
of Pathology, University of Bergen, Bergen, Norway
Email: Tien-sheng Huang - david.huang@gades.uib.no; Line M Myklebust - line.myklebust@mbi.uib.no; 
Endre Kjarland - endre.kjarland@biomed.uib.no; Bjørn Tore Gjertsen - Bjorn.Gjertsen@med.uib.no; 
Frederic Pendino - Frederic.Pendino@mbi.uib.no; Øystein Bruserud - Øystein.Bruserud@uib.no; 
Stein Ove Døskeland - Stein.Doskeland@biomed.uib.no; Johan R Lillehaug* - johan.lillehaug@mbi.uib.no
* Corresponding author    
Abstract
Background: Relapse due to chemoresistant residual disease is a major cause of death in acute
myelogenous leukemia (AML). The present study was undertaken to elucidate the molecular
mechanisms of chemoresistance by comparing differential gene expression in blasts from patients
with resistant relapsing AML and chemosensitive AML.
Results: About 20 genes were identified as preferentially expressed in blasts pooled from patients
with resistant disease, as compared to chemosensitive AML blasts, based on differential gene
expression screening. Half of these genes encoded proteins related to protein translation, of these
a novel protein related to the ribosomal stalk protein P0. Other upregulated mRNAs coded for
cytochrome C oxidase III, the transcription factors ERF-2/TIS11d, and the p75 and p52 splice
variants of Lens Epithelial Derived Growth Factor (LEDGF). Analysis of blasts from single patients
disclosed that LEDGF/p75 was the most consistently upregulated mRNA in resistant AML.
Transfection experiments demonstrated that LEDGF/p75 and p52b antagonized daunorubicin-
induced and cAMP-induced apoptosis in an AML cell line. Also HEK-293 cells were protected
against daunorubicin by LEDGF/p75 and p52b, whereas LEDGF/p52 splice variants lacking exon 6
had proapoptotic effects. Interestingly, full length LEDGF/p75 protected against truncated pro-
apoptotic LEDGF/p75.
Conclusion: Our results provide evidence for an association between the overexpression of
genes encoding survival proteins like LEDGF/p75 and chemo-resistance in acute myelogenous
leukemia. LEDGF/p75 has previously not been shown to protect against chemotherapy, and is a
potential drug target in AML.
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Background
Acute myeloid leukemia (AML) is an aggressive malignant
disorder characterized by neoplastic proliferation and
accumulation of immature myeloid cells. Most patients
achieve complete hematological remission after initial
induction chemotherapy, but a large part of these patients
will later develop leukemia relapse due to chemotherapy-
resistant residual disease [1-3]. The overall long-term (5
years) AML-free survival is therefore less than 50% even
for younger patients who receive the most intensive ther-
apy [2,3]. Chemoresistance can manifest either as primary
resistance to the induction therapy or as AML relapse fol-
lowing initial chemotherapy-induced hematological
remission. A high frequency of AML relapse is especially
observed in certain patient subsets characterized by per-
sistent leukemic disease after the initial induction cycle or
by high-risk cytogenetic abnormality [4,5]. Many of these
abnormalities affect genes that encode proteins involved
in the regulation of gene transcription [1]. Chemoresist-
ance after treatment with anticancer agents may also be
linked to perturbed gene expression [6,7]. These observa-
tions are consistent with altered gene expression being
involved in chemotherapy resistance. This notion is fur-
ther supported by two recent clinical studies describing
association between long-term disease-free survival and
particular gene expression profiles identified by cDNA
microarray screening [8,9]. The aim of the present study
was to identify genes overexpressed in chemoresistant
AML and in native AML cells derived from patients with
documented or high risk of clinical chemoresistance. For
this purpose, we used differential hybridization of pooled
RNA transcripts and confirmed the findings for each indi-
vidual patient using RNA dot-blot and RT-PCR analysis.
Our study demonstrated increased expression in chem-
oresistant cells of several gene products, notably lens epi-
thelial-derived growth factor (LEDGF)/p75 and a novel
gene called AML resistance associated protein (ARAP),
similar to ribosomal protein P0. Enforced expression of
the LEDGF/p75 and p52b genes protected against anthra-
cycline-induced apoptosis. Interestingly, other less
expressed splice variants of LEDGF were strong inducers
of apoptosis, but their effect was overcome by co-expres-
sion of the full length variant. Our study suggests that
AML cells express so far little known or unknown gene
products able to protect against chemotherapy, and that
naturally occurring pro-apoptotic splice variants can give
clues to domains of these proteins that can be pharmaco-
logical therapy targets.
Results
Identification of genes overexpressed in AML relapse cells
More than 25,000 colonies of our leukemia cDNA library
were screened with cDNA probes made from pooled
leukemia cell RNA from patients with chemosensitive
(L1-3) AML and from patients with AML resistant/
relapsed leukemia (R1–R5). We identified about 120 col-
onies with increased hybridization to cDNA probes from
R-cells. They were subjected to a secondary screening, in
which 19 putative genes were found to be upregulated
more than 2-fold. The genes were identified by DNA
sequencing (Table 1). One of the genes with increased (5-
fold) expression in the R-cells has not been described ear-
lier and consequently has not been associated with any
function so far. We refer to its predicted product as AML
resistance associated protein (ARAP). Two other genes
coded for known growth- and survival-associated tran-
scription factors, i.e. lens epithelium-derived growth fac-
tor (LEDGF) and the EGF response factor 2 (ERF-2). Most
of the upregulated genes coded for ribosomal proteins.
The translation-related Elongation Factor (EF)-1α also
showed increased expression. Three upregulated genes
coded for mitochondrial proteins, and two others for pro-
teins involved in antigen presentation or protein degrada-
tion. We also noted an upregulation of lysozyme.
The screening result for the genes with highest relative
expression in R-cells was validated by RT-PCR in the
pooled cDNA probes prepared from RNA of L- and R-cells.
Two sets of specific primers were used and rpP2 served as
a control for equal loading. The novel gene ARAP was con-
firmed to be relatively overexpressed in the R-cells (Fig. 1).
The LEDGF/p75 gene generates two transcripts by alterna-
tive RNA splicing, LEDGF/p75 and p52 mRNAs [10-12].
Both these transcripts showed increased levels in relapsed/
chemoresistant AML, as did the transcripts for the ribos-
omal proteins L6 and S4 (Fig. 1). From these data, we con-
clude that the R-cells had increased expression of several
genes associated with transcription, translation, mito-
chondrial function, and protein processing, suggesting a
possible reprogramming of several pivotal cell functions
of the blast cells from patients with chemoresistant AML.
We have recently found profound differences in phospho-
protein signaling cascades between AML cells from
patients with low-risk and high-risk of relapse [13]. Our L-
cells were from low-risk patients, and their expression of
9 of the genes presented in Table 1 was studied in cells
from individual patients. For comparison, we studied the
expression of the same genes in cells from individual
patients with high risk (H-cells) of relapse and the cells
from patients with resistance (R-cells) to chemotherapy
regimens (Table 1). It appeared that ARAP expression was
enhanced in 4 of the 5 R-cell patients, average more than
4-fold, but not increased in the H-cells. High expression of
this gene could therefore be a consequence of the chemo-
therapy. The genes encoding the transcription factors
LEDGF/p75 and ERF-2 were also generally more upregu-
lated in the R-cells than in the H-cells (Table 1). The other
genes studied were upregulated in at least half of the
patients whose R- and H-cells were studied. They wereMolecular Cancer 2007, 6:31 http://www.molecular-cancer.com/content/6/1/31
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generally equally or more upregulated in the H-cells than
in the R-cells, suggesting that previous chemotherapy was
not required for the overexpression. We conclude that
high-risk and low-risk AML cells differ not only with
respect to phospho-signalomics [13], but also with respect
to expression of the genes associated with AML relapse.
Most R and H patients had increased expression of a
number of the resistance-associated genes. We focused in
more detail on the LEDGF/p75 because it had the highest
relative expression in the R-cells relative to the L-cells
among the differentially expressed genes tested (Table 1)
and earlier studies indicating LEDGF/p75 to be involved
in cell survival [14,15].
LEDGF/p75/p52 mRNA splice variants in human AML cells
Both LEDGF/p75 and p52 were associated with chemore-
sistance in native human AML cells (Fig. 1). In subsequent
experiments, the full-length LEDGF/p75 and p52 cDNAs
were cloned by RT-PCR from the promyelocytic leukemia
NB4 cells. Additional novel spliced LEDGF/p75 mRNA
transcripts were detected by RT-PCR of the overlapping
region between LEDGF/p75 and p52, and these splicing
patterns were confirmed by RT-PCR using primers derived
from exon 3 and exon 8 (Fig. 2A). Subcloning and
sequencing of p52 cDNAs derived from NB4 AML cells
identified four previously unknown splice variants of the
LEDGF/p75/p52 gene (summarized in Fig. 2B). One,
p52b, had a p52-specific exon 9b. The putative amino
acid sequence of this novel and well expressed (Fig. 2A)
p52 mRNA variant was identical to p52 except for 25 extra
amino acid residues at the C-terminal end due to an
altered open reading frame. Three different low expres-
sion (Fig. 2A) variants without exon 6 are referred to as
p52bΔE6 (Fig. 2B), p52Δ1, and p52bΔ1. The P52bΔE6
Table 1: Genes preferentially expressed on chemotherapy-resistant AML relapse
Genes identified Primary differential screening mRNA expression Individual patients means of mRNA expression
R/L R/L H/L
Novel
ARAP 5.0 40. 0.9
Transcription factors
LEDGF/p75 4.8 7.7 2.8
ERF-2/TS11d 2.2 3.3 1.3
Translation-related
EF-1 3.2 3.2 3.4
rpL3 2.9
rpL6 4.5 2.8 4.7
rpL11 2.7
rpL34 2.7
rpL41 3.6
rpS4 5.3 3.8 3.5
rpS12 3.2
rpS24 2.7
rpS25 2.7
Mitochondria-related
CytOX II 2.4 2.1 2.5
CytOX III 4.0 2.3 3.7
ND4 2.7
Others
Lysozyme 4.2 2.3 4.1
MHC-DRA 3.6
PSME1/pAI 2.4
The results are based on primary differential screening of an AML cDNA library of more than 25,000 colonies. Probing was with cDNa probes 
derived from RNA of pooled native AML blasts from either patients sensitive to chemotherapy or from patients relapsing after several 
chemotherapy treatment courses. It also shows the means of mRNA expression in relapsed AML blasts relative to sensitive blasts from individual 
patients. [32P] cDNA derived from individual AML patient blasts (L1-3, R1-5 and H1-5) were used as probes for dot-blot analysis against nine of the 
genes found up-regulated in pooled RNA from resistant AML blasts. Only genes with expression ratio exceeding 2 are presented. L: low risk blasts; 
H, high risk blasts; ARAP, AML resistance associated protein; rp, ribosomal protein; CytOX II, III, cytochrome C oxidase subunit II and III; ND4, 
NADH dehydrogenase subunit 4; EF-1, elongation factor 1; PSME1/pAI, proteasome activator 28 subunit I; ERF-2/TIS11d, EGF response factor-2/
human homolog of TIS11d; LEDGF, lens epithelium derived growth factor, and MHC-DRA, major histocompatibility complex class II DR alpha.Molecular Cancer 2007, 6:31 http://www.molecular-cancer.com/content/6/1/31
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variant coded for a putative truncated protein due to a
stop codon introduced into the P52b reading frame,
whereas p52Δ1 and p52bΔ1 encoded proteins with gross
deletions (lack of exons 6, 7 and large parts of 5 and 8).
LEDGF/p75 can be expressed in a number of splice vari-
ants in AML cells. We wanted to know the possible func-
tional significance of the overexpression of LEDGF/p75 in
AML cells from patients with chemoresistance, and the
significance of the splice variants of p52 described. For
this purpose, we first used Flp-In 293 cells transfected
with the various genes and analyzed for induction of
spontaneous apoptosis or for ability to modulate the
apoptosis induction by daunorubicin.
Overexpression of LEDGF/p75 protected against 
daunorubicin-induced apoptosis, whereas LEDGF/p52 
splice variants without exon 6 were pro-apoptotic
We previously used transiently transfected HEK293 cells
to show that Bcl-2 protects against daunorubicin-induced,
but not okadaic acid induced apoptosis [16]. In the
present study, we compared the ability of transfected
LEDGF/p75 and Bcl-2 to protect against daunorubicin
induced apoptosis, using either a moderate drug concen-
tration (0.5 μM) for an extended period of time (16 h) or
a high concentration (5 μM) for a short period (1 h). In
either case, the protective effect of LEDGF/p75 was com-
parable with that of Bcl-2, transfected under similar con-
ditions (Fig. 3). We found significantly increased survival,
as compared to cells transfected with empty vector, for
cells transfected with LEDGF/p75 (p < 0.01). We conclude
that LEDGF7p75 consistently overexpressed in resistant
and high-risk AML patient cells were indeed able to pro-
tect against a first line anti-leukemic drug.
We investigated next the effect of LEDGF/p75 splice vari-
ants on in vitro apoptosis of Flp-In 293 cells. First, the
effect of the splice variants was investigated for spontane-
ous apoptosis in cells cultured in medium alone. A
decreased number of viable cells was observed for cells
transfected with the three splice variants lacking exon 6
(p52Δ1, p52bΔ1, p52bΔE6, see Fig. 2) compared with
cells transfected with the control vector (Fig. 4). A similar
decrease in viability was also observed when testing an
artificial LEDGF/p75317–530 gene segment encoding only
the 317–530 amino acids of the C-terminal domain and
thereby lacking overlap with p52 (Fig. 4). In contrast, a
high viability was observed both when testing cells trans-
fected with the control vector and with the p52b splice
variant containing exon 6. The non-viable cells had mor-
phology consistent with apoptosis in all these cultures.
Thus, the 3 splice variants without exon 6 seemed to
mediate proapoptotic effects. Secondly, a similar differ-
ence between splice variants without exon 6 and the p52b
variant was observed for daunorubicin-induced apoptosis
(0.5 μM daunorubicin, 16 hrs exposure), but the differ-
ences were smaller than for spontaneous apoptosis (Data
not shown). Finally, the effect of the four p52 splice vari-
ants was also determined for Flp-In 293 cells transfected
with LEDGF/p75 and exposed to daunorubicin as
described above. LEDGF/p75 antagonizes daunorubicin-
induced apoptosis, and the number of viable cells did not
differ between the four p52 splice variants in these exper-
iments.
Overexpression of LEDGF/p75 and p52b in IPC81 AML 
cells protected against apoptosis induced by daunorubicin 
or cAMP analog
Since the LEDGF/p75 overexpression was found in resist-
ant AML cells, it was important to know whether overex-
pression of LEDGFp75 and p52b also could protect AML
cells. For this, we chose the highly anthracyclin-sensitive
IPC-81 rat AML cell line [17], which originates from the
BNML rat model of leukemia, known to be a reliable pre-
dictor of treatment success for chemotherapy agents in
current clinical use against AML [18]. These cells are also
highly sensitive to apoptosis induction by activation of
the cAMP-dependent protein kinase [19,20]. In order to
achieve efficient gene transfer, the LEDGF/p75 and p52b
constructs were delivered via a retroviral system. In order
to visualize transduced cells, the LEDGF/p75 genes were
cloned in tandem with a GFP gene governed by an inter-
nal ribosome entry site. We found that cells with enforced
expression of either LEDGF/p75 or p52b were signifi-
cantly protected against apoptosis induced by either dau-
norubicin or cAMP analog (Fig. 5). We conclude that both
LEDGF/p75 and p52b are able to protect against AML
death in vitro, suggesting that their consistent overexpres-
sion in AML cells from treatment – resistant AML is not
coincidental.
Effects of daunorubicin on LEDGF/p75 expression in 
human NB4 AML cells
The regulation of LEDGF/p75 expression was investigated
in NB4 human AML cells. We analyzed LEDGF/p75
mRNA expression in serum-starved NB4 cells, and signifi-
cantly increased LEDGF/p75 mRNA levels were observed
after 24 and 48 hours (Fig. 6A). We then investigated the
effect of daunorubicin on expression of LEDGF/p75
mRNA and its protein. rpP2 cDNA as a standard reference
in the RNA preparations. LEDGF/p75 mRNA was signifi-
cantly increased in cells treated with 30 nM and 90 nM
daunorubicin for 18 hours (<10% and 40–50% apopto-
sis, respectively), whereas LEDGF/p75 mRNA levels were
reduced and a majority of cells were apoptotic (approx.
90%) when cells were exposed to 180 nM daunorubicin
(Fig. 6B). The levels of LEDGF/p75 protein in total protein
extracts from NB4 cells were further analyzed by western
blot analysis using anti-LEDGF/p75 antibodies. A 75 kDa
band specific of LEDGF/p75 increased in the presence ofMolecular Cancer 2007, 6:31 http://www.molecular-cancer.com/content/6/1/31
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30 and 90 nM daunorubicin (Fig. 6C), whereas after expo-
sure to 180 nM daunorubicin, degradation of LEDGF/p75
was observed with the formation of a novel protein band
of approximately 58 kDa. This new protein seems to be a
relatively stable LEDGF/p75 degradation product gener-
ated by caspase 3 mediated cleavage during apoptosis
[21].
Discussion
The present differential gene display analysis identified a
number of genes with increased expression in relapsed
AML. The increase of each mRNA varied between patients,
in keeping with our recent study [13] which revealed dif-
ferent response of signaling pathways coupled to transla-
tional control in a similar panel of patient AML cells. Also
array-based AML gene expression profiling studies [9,22-
24] underscore the heterogeneity of AML and the need for
personalized therapy [25,26].
A strikingly high proportion of the genes with increased
expression in relapsed AML (Fig. 1) were related to protein
translation. One of them, termed ARAP, has sequence
similarities to ribosomal protein P0 and has not previ-
ously been cloned. The elucidation of ARAP function and
the role proteins involved in protein translation will be
the subject of future studies.
Importantly, we found increased mRNA levels in relapsed
AML for the general transcriptional co-activator lens epi-
thelium derived growth factor (LEDGF)/p75 and its splice
product p52 [11]. The LEDGF/p75 mRNA was the most
consistently upregulated in our series of relapsed AML.
AML cells transfected with LEDGF/p75 or p52b were sig-
nificantly more resistant to apoptosis induction in vitro by
either daunorubicin or the presumed physiological apop-
togen cAMP (Fig. 5). Detailed studies in HEK293 cells
showed that overexpression of LEDGF/p75 protected
against daunorubicin-induced death to a similar extent as
bcl-2 (Figs. 3, 4), suggesting that increased LEDGF/p75
might enhance chemotherapy resistance also in non-AML
cells. This finding is consistent with LEDGF/p75 protect-
ing cells against stress such as serum deprivation [14].
LEDGF/p75 and p52 share the same 325 N-terminal resi-
dues, in which is found a PWWP domain (residues 1–
100) interacting with stress response elements, a nuclear
localization signal (residues 146 – 156), and an AT-hook
motif (residues 179–198) [14]. Although p52 only has 8
unique C-terminal amino acids, it can interact selectively
with the splicing factor ASF/SF2 [12]. The unique C-termi-
nal 205 residues of LEDGF/p75 harbor a hepatoma
derived growth factor homology domain that binds to
chromatin even in the absence of a functional NLS [27].
The pro-survival function of LEDGF/p75 is believed to
depend on the 44 C-terminal residues since LEDGF/p75
(1–486) failed to protect hepatoma cells against serum
deprivation [21]. We found that p52b, which lacks the C-
terminal residues of LEDGF/p75 (Fig. 2) did not induce
apoptosis but our data suggest that it has some protective
activity against daunorubicin-induced death (Fig. 4). This
Confirmation of preferential gene expression in chemother- apy-resistant AML Figure 1
Confirmation of preferential gene expression in 
chemotherapy-resistant AML. The expression of the 
genes found by primary differential screening to have the 
highest relative expression in resistant AML blasts (Table 1) 
was reinvestigated by RT-PCR of RNA pooled from resistant 
(R; left column) or low risk (L; right hand column) AML 
blasts. The level of rpP2, used to normalize expression of the 
other genes, was also studied. The R-blasts were from 
patients with relapse from chemotherapy (R1-5) and the L-
blasts from chemo-responsive patients (L1-3). See the Mate-
rial and methods section for further details on patients, cells 
and RT-PCR procedure.Molecular Cancer 2007, 6:31 http://www.molecular-cancer.com/content/6/1/31
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The expression and characterization of LEDGF/p75 splice variants in NB4 cells Figure 2
The expression and characterization of LEDGF/p75 splice variants in NB4 cells. A) The splicing pattern of LEDGF/
p75 mRNA in NB4 cells as revealed by RT-PCR. The primers (p75-1; from exons 1 and 9) used for lane 1 (left) and (p75-2; 
exons 3 and 8) used for lane 2 (right) were from the common region of LEDGF/p75 and p52. The identity of the splice variants 
marked in lane 2 was verified by DNA sequencing. B) Schematic representation of the p52 splice variants. The identical N-ter-
minal domain of LEDGF/p75 and p52 is indicated as exon 1 to exon 9. The p52 variant contains an alternative exon 9b with a 
poly (A) tail at its C-terminal end, whereas C) p52b differs from p52 by lacking 55 bases in the alternative exon 9b. The low 
expression p52bΔE6 variant lacks exon 6 at its N-terminal region and has a frameshift that introduces several stop codons, 
whereas p52Δ1 and p52bΔ1 lack exons 6, 7 and parts of 5 and 8. // indicates omitted exons in the figure.Molecular Cancer 2007, 6:31 http://www.molecular-cancer.com/content/6/1/31
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Effects of LEDGF/p75 and bcl-2 on daunorubicin-induced apoptosis Figure 3
Effects of LEDGF/p75 and bcl-2 on daunorubicin-induced apoptosis. Flp-In 293 cells were transfected with control 
vector pcDNA3.1 or vectors containing either LEDGF/p75 or bcl-2. All transfected cells treated with vehicle alone (Ctl) had 
normal morphology. After treatment with 0.5 μM daunorubicin (DNR) for 16 h only 22% of the cells transfected with control 
vector appeared morphologically viable, against 47 and 42% for cells transfected with either LEDGF/p75 or bcl-2. Also cells 
treated with 5 μM daunorubicin for 1 h were protected by transfection with either LEDGF/p75 or bcl-2. Cell viability was ana-
lysed as described in the Materials and Methods section. Results are presented as the mean of viable cells ± SEM of separate 
experiments performed in triplicate (n = 3).Molecular Cancer 2007, 6:31 http://www.molecular-cancer.com/content/6/1/31
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suggests that the C-terminal 205 residues of LEDGF/p75
were dispensable for protection against cell death. In fact,
enforced expression of LEDGF/p75 (317–530) not only
failed to protect against daunorubicin but induced signif-
icant death by itself (Fig. 4). The finding that p52 is not
pro-apoptotic helps understand why patient leukemic
cells with cytogenetic abnormality, t(9;11), involving the
NUP98 gene and encoding NUP98-LEDGF/p75/p52
fusion proteins, have a high expression of both the
LEDGF/p75 and p52 fusion products [28-30].
LEDGF/p75 and p52 were also present in NB4 AML cells,
in which we detected four additional novel p52 variants,
three of which had deleted exon 6. One variant
(p52bΔE6) lacked only exon 6, while the others (p52Δ1,
p52bΔ1) also lacked exon 7 and parts of exons 5 and 8
(Fig. 2). Exon 6 codes for residues important both for the
NLS and the AT-hook of LEDGF/p75, and its absence will
therefore presumably abolish or alter the nuclear localiza-
tion of p52. All three p52 splice variants lacking exon 6
enhanced rather than protected against daunorubicin-
induced death (Fig. 4). This means that the LEDGF/p75
gene can create both pro- and anti-apoptotic proteins. We
found that full-length LEDGF/p75 protected against all
three pro-apoptotic splice variants of p52 as well as
against the pro-apoptotic p75 (317–530) fragment of
LEDGF/p75 (Fig. 4). This suggests that increased expres-
sion of full-length LEDGF/p75 may protect against pro-
apoptotic p52 splice variants as well as against truncated
LEDGF/p75 variants produced by caspase-dependent
processing of LEDGF/p75 [21]. The high expression of
LEDGF/p75 in relapsed AML may therefore protect
against apoptosis both by stimulating the transcription of
other survival genes and by partially blocking the effect of
pro-apoptotic shorter versions of LEDGF/p75 and p52.
Conclusion
In summary, relapsed as well as "high risk" AML cells have
increased expression of several genes encoding novel as
well as known anti-apoptotic proteins. Few of these genes
have previously been implicated in AML drug resistance.
The LEDGF/p75 gene, as well as several pro-apoptotic
splice variants of p52, in NB4 and AML (IPC81) cells have
not been described before. A striking observation is the
heterogeneity with regard to which genes that are upregu-
lated, identifiable in the present study. This confirms that
AML is a heterogeneous disease. We consider LEDGF/p75
to be a potential, novel therapeutic target in relapsed AML
since it was among the genes most consistently upregu-
lated and because it provided resistance towards daunoru-
bicin after transfection. The LEDGF/p75/p52 molecule
has both pro- and anti-apoptotic subdomains, the exact
extent and function of which is only beginning to be
unraveled. One strategy for improved chemotherapy of
cancer cells with overexpression of LEDGF/p75 can be to
remove the anti-apoptotic function inherent in the resi-
dues coded by exon 6, by first studying the effect of abol-
ishing the NLS and the AT-hook present in this region.
Methods
Patients
AML blasts were collected from the peripheral blood of 13
patients. Blasts were collected from 3 patients with
chemo-sensitive AML at the time of diagnosis ("low risk",
L1-3). All had complete hematological remission after the
first induction cycle. Two are still alive 93 and 109 months
after diagnosis, respectively; the third had 44 months of
disease-free survival even though consolidation therapy
could not be completed due to serious side effects. All
three had low/intermediate risk of relapse [4,31] judged
from cytogenetics (two inv(16), one normal) and no
genetic Flt3 abnormality. AML cells were collected from
five patients who had undergone previous intensive ther-
apy, (i) two patients had relapse after intensive chemo-
therapy and allotransplantation, respectively, and (ii)
three patients had primary resistant disease and did not
reach remission after three induction cycles. For compari-
son, cells were collected at the time of primary diagnosis
from patients with high risk of resistance/relapse [31-33].
AML ("high-risk", H1-5). Two patients (H1, 2) had AML
secondary to primary myelodysplastic syndrome (MDS),
and treatment was not attempted, whereas the three last
patients (H3-5) later showed resistance to at least two dif-
ferent induction regimens. All human samples were col-
lected in accordance with the Helsinki Declaration.
Preparation of native AML blasts
Leukemic peripheral blood mononuclear cells (PBMC)
were collected from peripheral blood, and isolated by
density gradient separation (Ficoll-Hypaque; NyCoMed,
Oslo, Norway; specific density 1.077) [34,35]. Cells were
stored in liquid nitrogen until use. The percentage of
blasts among leukemic PBMC exceeded 95% for all
patients, as judged by light microscopy of May-Grünwald-
Giemsa stained smears.
Culturing, transfection and apoptosis scoring in cell lines
Flp-In 293 cells (Invitrogen) were cultured in DMEM
medium supplemented with 10% heat-inactivated fetal
bovine serum. The p52 specific splice variants were cloned
into pcDNA3.1/V5-His TOPO (Invitrogen). LEDGF/p75
in pcDNA3.1/His was a generous gift from C. A. Casiano
(St. Loma Linda University, USA). Cells were cultured and
transfected using FuGENE-6 (Boehringer Mannheim)
according to the manufacturer's protocol. After 24 h, cells
were diluted to desired number and seeded into collagen
coated 12-well plates. Cells were fixed by 4% buffered
paraformaldehyde after DNR treatments. Cells were
examined for daunorubicin-induced apoptosis by fluores-
cence microscopy after DNA staining [16,34]. For estima-Molecular Cancer 2007, 6:31 http://www.molecular-cancer.com/content/6/1/31
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tion of statistical significance of values for percentage of
apoptosis, we used the non-parametric Wilcoxon paired
comparison test.
Effects of LEDGF/p52 splice variants on spontaneous and  daunorubicin-induced apoptosis Figure 4
Effects of LEDGF/p52 splice variants on spontaneous 
and daunorubicin-induced apoptosis. Flp-In 293 cells 
were cultured in medium without (A), or with 0.5 μM dauno-
rubicin (DNR) for 16 hours (B, C). The cells were trans-
fected with control vector (pcDNA3.1), p52b (with exon 6), 
with p52Δ1, p52bΔ1 or p52bΔE6 (all of which lack exon 6), 
or with LEDGF/p75317-530, i.e. the part of the LEDGF/p75 
gene (exons 10–15) that do not overlap with p52. In panel C, 
cells were co-transfected with full length LEDGF/p75 and 
p52Δ1, p52bΔ1, p52bΔE6, or C-LEDGF/p75317-530. Scoring 
of cell viability and other experimental conditions are as 
described in the legend to Fig. 5.
Expression of LEDGF/p75 mRNA and protein in NB4 cells  treated with daunorubicin Figure 6
Expression of LEDGF/p75 mRNA and protein in NB4 
cells treated with daunorubicin. A) Expression of 
LEDGF/p75 mRNA in NB4 cells treated with serum starva-
tion analyzed by RT-PCR. Cell were cultured under serum-
free (SF) conditions for 24 and 48 hours before analysis; 
untreated NB4 cells served as control cells (Ctl). Primers for 
the rpP2 gene were also included as a control. The RT-PCR 
results are representative of at least three independent 
experiments. B) The expression of LEDGF/p75 and ARAP 
mRNA in NB4 cells exposed for 18 h to daunorubicin (DNR) 
at 30, 90, or 180 nM. C) Western blot analysis of NB4 cells 
exposed to DNR as described above. Note the disappear-
ance of full length LEDGF/p75 (75 kDa) and formation of a 
degradation product * (58 kDa) after exposure to 180 nM 
DNR.Molecular Cancer 2007, 6:31 http://www.molecular-cancer.com/content/6/1/31
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Enforced expression of LEDGF/p52b and LEDGF/p75 counteracted leukemic cell death induced by DNR or cAMP analog Figure 5
Enforced expression of LEDGF/p52b and LEDGF/p75 counteracted leukemic cell death induced by DNR or 
cAMP analog. The upper panels show differential interference contrast micrographs of IPC-81 leukemia cells with enforced 
expression of GFP (A-C) or bicistronic expression of LEDGF/p75 and GFP (D-F), and treated 20 h with vehicle (A, D), 10 nM 
DNR (B, E), or 10 μM 8-pCPT-cAMP (C, F). The lower panel (G) shows % apoptosis (mean ± SEM, n = 5) of IPC cells after 20 
h treatment with 10 nM DNR (open bars) or 10 μM 8-pCPT-cAMP (solid bars). Note the lower % apoptosis in cells expressing 
LEDGF/p75 and LEDGF/p52b than in cells expressing GFP.Molecular Cancer 2007, 6:31 http://www.molecular-cancer.com/content/6/1/31
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Cell culturing, virus production and assessment of 
apoptosis
The promyelocytic leukemia cell line IPC-81 and NB4
cells were generous gifts from Dr M Lanotte (INSERM U-
496, Centre G Hayem, Hospital St Louis, Paris, France).
The cells were cultured in Dulbecco's modified Eagle's
medium (DMEM, Invitrogen) under standard conditions
supplemented with 10% heat-inactivated horse serum
(Invitrogen), streptomycin (5 μg/ml) and penicillin (5 U/
ml). Cells were kept in logarithmic growth, and as a stand-
ard procedure, cell density was adjusted to 0.2 × 106 cells/
ml before addition of drugs. The cyclic AMP analog 8-
chlorophenylthio-cAMP (8-CPT-cAMP) was purchased
from Biolog Life Science, Bremen, Germany. Daunoru-
bicin (DNR) was purchased from Sigma-Aldrich Inc. (St
Louis, MO, USA).
Phoenix-Eco virus producer cells and CRU5-IRES-GFP ret-
rovirus vector were kindly provided by Dr. J. Lorens
(Department of Biomedicine, University of Bergen) and
the cells were maintained in DMEM supplemented with
10% heat-inactivated fetal calf serum (Invitrogen). The
full-length cDNAs of LEDGF/p75 and p52b with Bst XI
linker were cloned into CRU5-IRES-GFP.
Retrovirus were pseudotyped with the vesicular stomatitis
virus glycoprotein (VSVG) and concentrated by ultracen-
trifugation essentially as described [36]. Briefly, 1.5 × 106
Phoenix cells plated the day prior to transfection using the
calcium phosphate method, 2 μg retroviral plasmid and 2
μg VSV-G. After 48 hours, filtered supernatants were con-
centrated by centrifugation for 3 hours at 50 000 g, 4°C.
IPC-81 cells (0.5 × 106) were transduced by spin infection
in which a mixture of virus and cells was centrifuged at
1200 g for 90 minutes at room temperature in the pres-
ence of protamine sulphate (5 mg/ml, Sigma-Aldrich).
Routinely, 90–95% of the cells showed fluorescence 48
hours after infection. After treatment, cells were fixed in
phosphate-buffered saline containing 2% formaldehyde.
Screening for apoptosis was done blindly by two inde-
pendent experienced evaluators using phase contrast
microscopy to study surface morphology and nuclear
morphology as visualised by the DNA-specific stain bis-
benzimide, Hoechst 33342 (Sigma-Aldrich). Three differ-
ent fields were randomly selected for counting at least 300
cells. All experiments were repeated at least five times. Per-
cent apoptosis is defined as the ratio between cells with
both membrane budding and chromatin condensation
and the total of cells counted.
Differential screening of a leukemia cDNA library
The construction of a leukemia cDNA library and hybrid-
ization was as described previously [37]. The SMART sys-
tem (Clontech) was used to construct a cDNA library
from the pooled RNA collected from AML patient cells
(Table 1; S1 to S3 and R1 to R5). The UV-cross linked
replica membranes with total over 25,000 colonies were
subjected to primary screening by radio-labeled first
strand cDNA from the pooled RNA of either "low risk"
(L1-3) or "resistant" (R1-5) AML cells. Colonies with dif-
ferent signal intensity towards cDNA derived from resist-
ant and sensitive AML were subjected to a second round
of screening. DNA sequence reactions were carried out
by the BigDye terminator method and analyzed by auto-
matic sequencing (ABI PRISM). The BLAST search pro-
gram was used for homology search (National Center for
Biotechnology Information, Bethesda, MD).
Dot-blot analysis of differentially expressed genes in cells 
from individual AML patients
Gene fragments from selected differentially expressed
genes were amplified from plasmids by PCR using T7
promoter and M13 reverse primers. The amplified spe-
cific PCR fragments were used in dot-blot analysis using
32P-labeled cDNA probes from RNA of L1, 2, 3; R1, 2, 3,
4, 5 and H1, 2, 3, 4, and 5. The membranes were ana-
lyzed by phospho-imaging, and the hybridization signal
normalized to the mRNA expression level of the ribos-
omal protein P2 (rpP2) gene for sample from each AML
patient.
5'-RACE experiments
The 5'-end of ARAP mRNA was obtained by using 5'Gen-
eracer kit (Invitrogen) with primers described in the kit
and antisense primers designed from the cDNA
sequence. The antisense primers, 5'-GTCATCATCTTCT-
GAGTCTGACTC-3' and 5'-CACCATCATCACCTT-
GTTTTTGCC-3', were used for PCR amplification.
Relative mRNA expression determined by RT-PCR
Total RNA from either NB4 cells or from patient AML
blasts pooled from S1-3 or R1-5 was used for ss cDNA
synthesis using oligo-(dT)-primer and superscript II
reverse transcriptase (Invitrogen). The PCR reaction (50
μl) contained 1 μl cDNA and specific 5'-and 3'-primers.
The PCR products were collected after 21–24 cycles of
amplification. The primers were: rpL6, 5'-ATGGCGGGT-
GAAAAAGTTGAGAAGC-3' and 5'-GTAGAACAC-
CAATTTGTGAGGA-3'; rpS4, 5'-
ATGGCTCGTGGTCCCAAGAAGCATC-3' and 5'-GCAC-
CCACTGCTCTGTTTGGCCGCC-3'; ARAP, 5'-
CAAAAACAAGGTGATGATGATGG-3' and 5'-CCAGAG-
GGGCGGCAGCAGTCC-3'; Primers for full-length
ARAP, 5'-ATGCCCAAATCCAAGCGCGACAA-3' and 5'-
GTCATCATCTTCTGAGTCTGACTC-3'; LEDGF/p75, 5'-
ATGACTCGCGATTTCAAACCTGGA-3' and 5'-
GTTATCTAGTGTAGAATCCTTCAGA-3'; p52, 5'-
ATGACTCGCGATTTCAAACCTGGA-3' and 5'-GTC-
CAATGAGTCTGTATCAAGATC-3'; p75-1, 5'-
ATGACTCGCGATTTCAAACCTGGA-3' and 5'-GATCT-Molecular Cancer 2007, 6:31 http://www.molecular-cancer.com/content/6/1/31
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TCATCTCTTGTTTGCTCCAC-3'; P75-2, 5'-AAGCCAC-
CCACAAACAAACTACCC-3' and 5'-
CCCTCCTTTTCTCTTCTTTTCTCC-3'; rpP2, 5'-
ATGCGCTACGTCGCC-3' and 5'-TTAATCAAAAAG-
GCCAAATCCCAT-3'.
Western blot analysis
Cell pellets were lyzed in ice-cold 10 mM Tris pH 7.5 with
0.5% NP-40, 1 mM MgCl2, 1 mM DTT, 10 mM KCl, 0.4 M
NaCl for 5 min, and centrifuged at 11,000× g for 5 min.
50 μg supernatant protein was separated by 12% SDS-
polyacrylamide gel electrophoresis under reducing condi-
tions and transferred to a nitrocellulose filter. The mem-
brane was probed with anti-LEDGF/p75 polyclonal
antibodies (kindly provided by C. A. Casiano) and the
membrane was developed using the enhanced ECL detec-
tion method (Amersham Biosciences, Uppsala, Sweden).
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